Mode
Text Size
Log in / Sign up

Adjunctive intracoronary thrombolysis reduces major adverse cardiovascular events in patients with STEMIIntracoronary Thrombolysis Linked to Lower Risks After Heart Attack

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider adjunctive intracoronary thrombolysis to potentially reduce MACE and improve reperfusion in STEMI patients.

The researchers analyzed the outcomes of adjunctive intracoronary thrombolysis compared to primary percutaneous coronary intervention alone in patients presenting with ST-segment elevation myocardial infarction. The primary objective was to determine if adding thrombolytic agents during the procedure influenced major adverse cardiovascular events.

The analysis reported a lower risk of major adverse cardiovascular events for those receiving adjunctive thrombolysis. Additionally, several secondary outcomes related to myocardial reperfusion showed improvement, including better TIMI flow grades, improved myocardial perfusion grades, and enhanced ST-segment resolution. These findings were associated with reduced corrected TIMI frame counts. Regarding safety, the authors found no significant difference in major bleeding between the two groups.

A primary limitation noted by the authors is the heterogeneity of the randomized data included in the analysis. Clinically, while the results suggest that adjunctive thrombolysis may improve reperfusion markers and reduce adverse events without increasing bleeding risks, the heterogeneous nature of the evidence necessitates a cautious approach when integrating these findings into standard practice for STEMI management.

A meta-analysis looked at 2,604 patients who suffered from ST-segment elevation myocardial infarction (STEMI). These patients underwent primary percutaneous coronary intervention (PCI), which is a common procedure to open blocked heart arteries. The study compared standard treatment against adding intracoronary thrombolysis during the procedure.

The results showed that patients who received the extra thrombolysis had a significantly lower risk of major adverse cardiovascular events. The data also indicated improvements in several markers of blood flow and heart health, such as better ST-segment resolution and improved myocardial perfusion grades. These findings suggest the treatment helps restore blood flow more effectively.

Safety was also monitored, specifically regarding major bleeding. The study found no significant difference in major bleeding rates between the two groups. However, it is important to note that these results come from heterogeneous randomized data, which can vary across different studies. Patients should discuss these findings with their doctors to see how this approach fits their specific heart health needs.

What this means for you:
Adding intracoronary thrombolysis during certain heart procedures may lower risk and improve blood flow markers.

Common questions

What are the benefits of using intracoronary thrombolysis?

The study found that adding this treatment during a procedure led to a significantly lower risk of major adverse cardiovascular events. It also showed improvements in blood flow markers, such as better ST-segment resolution and improved myocardial perfusion grades for patients with a STEMI.

Is it safe to use this treatment for heart conditions?

The study compared the treatment against standard care and found no significant difference in major bleeding rates. While the procedure is associated with better blood flow markers, you should talk to your doctor about specific risks and benefits.

How does this differ from standard heart procedures?

Standard treatment involves primary percutaneous coronary intervention (PCI). This study looked at adding intracoronary thrombolysis to that procedure. The addition was linked to better angiographic results and a lower risk of major complications.

Study Details

Study typeMeta analysis
Sample sizen = 2,604
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Restoration of epicardial patency with primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) does not necessarily translate into adequate tissue-level reperfusion. Adjunctive intracoronary thrombolysis has been proposed to improve microvascular perfusion, but randomized data remain heterogeneous. This study sought to evaluate the efficacy and safety of adjunctive intracoronary thrombolysis during primary PCI for STEMI. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing adjunctive intracoronary thrombolysis plus primary PCI versus control in patients with STEMI. The primary endpoint was major adverse cardiovascular events (MACE). Secondary endpoints included major bleeding, post-procedural TIMI flow grade 2/3, TIMI myocardial perfusion grade, ST-segment resolution, and corrected TIMI frame count (CTFC). Random-effects models were used to estimate pooled treatment effects. Fifteen RCTs with 2,604 patients were included. Compared with control, adjunctive intracoronary thrombolysis was associated with a significantly lower risk of MACE (risk ratio [RR]: 0.66; 95% confidence interval [CI]: 0.52 to 0.84; p < 0.001). Intracoronary thrombolysis also improved postprocedural TIMI flow grade 2/3 (RR: 1.08; 95% CI: 1.02 to 1.13; p = 0.005), TIMI myocardial perfusion grade (RR: 1.25; 95% CI: 1.08 to 1.43; p = 0.002), and ST-segment resolution (RR: 1.17; 95% CI: 1.10 to 1.25; p < 0.001), and reduced CTFC (mean difference: -4.49 frames; 95% CI: -6.25 to -2.72; p < 0.001). Major bleeding was infrequent and did not differ significantly between groups (OR: 1.40; 95% CI: 0.63 to 3.11). In STEMI patients undergoing primary PCI, adjunctive intracoronary thrombolysis was associated with lower MACE and improved angiographic and electrocardiographic markers of myocardial reperfusion without a significant increase in major bleeding.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.